Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia

Jarbrink K, Kreif N, Benedict A, Locklear J

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by CRD

MeSH
Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Dibenzothiazepines; Humans; Quality-Adjusted Life Years; Schizophrenia

AccessionNumber
22009102489

Date bibliographic record published
27/01/2010